Administration of the JAK1/STAT3 pathway inhibitor, baricitinib, resulted in impaired HCC cell growth and induced apoptosis, suggesting potential applications of JAK/STAT inhibitors and reagents in human HCC therapy. The gene discussed is JAK1; the disease is hepatocellular carcinoma.